Xpert MTB/RIF: Monitoring response to tuberculosis treatment

The Lancet Respiratory Medicine

Volumn 1, Issue 6, 2013, Pages 427-428

  Nicol, Mark P ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; AUTOMATION; BACTERIUM CULTURE; DNA DETERMINATION; DRUG MONITORING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; LETTER; MIXED INFECTION; NONHUMAN; NUCLEIC ACID AMPLIFICATION; PRIORITY JOURNAL; PROGNOSIS; PUBLICATION; REAL TIME POLYMERASE CHAIN REACTION; SPUTUM SMEAR; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; LUNG TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; SENSITIVITY AND SPECIFICITY;

HUMANS; MYCOBACTERIUM TUBERCULOSIS; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84881377789     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(13)70133-4     Document Type: Letter

References (7)

1. Policy statement: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system 2011, WHO, World Health Organization, Geneva.
2. Horne DJ, Royce SE, Gooze L, et al. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect Dis 2010, 10:387-394.
3. Fitzwater SP, Caviedes L, Gilman RH, et al. Prolonged infectiousness of tuberculosis patients in a directly observed therapy short-course program with standardized therapy. Clin Infect Dis 2010, 51:371-378.
4. Friedrich SO, Rachow A, Saathoff E Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respir Med 2013, on behalf of the Pan African Consortium for the Evaluation of Anti-tuberculosis Antibiotics (PanACEA), published online July 1. http://dx.doi.org/10.1016/S2213-2600(13)70119-X.
5. Banada PP, Sivasubramani SK, Blakemore R, et al. Containment of bioaerosol infection risk by the Xpert MTB/RIF assay and its applicability to point-of-care settings. J Clin Microbiol 2010, 48:3551-3557.
6. Helb D, Jones M, Story E, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 2010, 48:229-237.
7. Miotto P, Bigoni S, Migliori GB, Matteelli A, Cirillo DM Early tuberculosis treatment monitoring by Xpert(R) MTB/RIF. Eur Respir J 2012, 39:1269-1271.